Meet the CEOs Webcast Replay

This week join 3 CEOs of exciting ASX listed businesses, they will be giving valuable insight to their industries and companies future prospects.

  • Dennis Karp, from Manuka Resources
  • Sol Lukatsky, from Spirit Telecom (ST1.ASX)
  • Matthew Liddelow, from Neuroscientific Biopharmaceuticals (NSB.ASX)

Recorded on 10th June 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to the Reach Markets team

FEATURE SPEAKERS

DENNIS KARP

Executive Chairman

Manuka is Australia’s newest gold & silver producer and commenced production in April 2020 and is expected to mine and process over 30,000 ounces of gold in its first 12 months. Manuka owns 100% of two, fully permitted Gold and Silver assets located in the Cobar Basin of NSW. Manuka Resources purchased the Wonawinta project in late 2016 and acquired Mt Boppy Resources P/L the holder of the high-grade historic Mt Boppy gold project, in mid-2019. The Company expects to list on the Australian Securities Exchange (ASX) on the 14th of July 2020.

SOL LUKATSKY

Managing Director

Spirit Telecom (ASX:ST1) has been built on the simple premise that Australian businesses deserve better, faster and more reliable internet – and it’s grown rapidly to become a leading provider of high speed internet and IT & managed services to SMBs and essential industries such as hospitals, schools, aged-care and government. Spirit Telecom is a nimble company that is achieving high-growth due to its compelling service offering and delivery for clients, along with its smart, disciplined acquisition strategy. Now firmly established as a challenger brand with the infrastructure and expertise to take on the industry giants, Spirit Telecom is accelerating its growth plans, via its digital platform Spirit X and through acquisitions.

MATTHEW LIDDELOW

Chief Executive Officer and Managing Director

NeuroScienfitic Biopharmaceuticals Ltd (ASX: NSB) is a drug development company focused on developing novel peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. NSB’s lead drug candidate, called EmtinB, is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. EmtinB is in the advanced preclinicalphase of development with clinical development set to start by the end of 2020.

latest other webcasts

Felix Gold (ASX: FXG) Webcast Replay

Far East Gold (ASX: FEG) Webcast Replay

Prescient Therapeutics (ASX: PTX) Webcast Replay

Speak to the Reach Markets team




What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.